GH Research PLC (GHRS) Stock Analysis
Verdict: HOLD
GHRS offers a high-risk psychedelic play with a $246M cash fortress, but current price momentum is testing overstretched valuation limits.
Investment score: 64/100
Analysis as of
Is GH Research PLC stock worth reviewing? The TradeMates thesis
GHRS is a pre-revenue biotech with a superior balance sheet vs peers and high technical momentum. An entry is supported by strong analyst consensus, though volatility is guaranteed.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 80/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
GH Research PLC opportunities and risks
What speaks for GHRS
- Superior Cash Runway
What speaks against GHRS
- Binary Clinical Outcome Risk
Peers and competitors
- JAZZ
- PRGO
- COPN.SW
- ITRMF
- NBRVF
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GHRS | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.3% |
| JAZZ | 592.1x | 3.4x | 34.6x | 84.1% | 0.7% | 8.2% |
| PRGO | n/a | 0.4x | n/a | 34.2% | -43.5% | 7.1% |
| ITRMF | n/a | 6.8x | n/a | -171.3% | -5225.4% | -589.4% |
| NBRVF | n/a | 0.0x | 0.1x | 19.9% | -160.3% | -11430959.8% |
| Peer median | n/a | 1.9x | n/a | 27.0% | -101.9% | -291.2% |
Frequently asked questions about GH Research PLC (GHRS)
Is GHRS stock a good investment?
The TradeMates model rates GH Research PLC as HOLD with an investment score of 64/100. GHRS is a pre-revenue biotech with a superior balance sheet vs peers and high technical momentum. An entry is supported by strong analyst consensus, though volatility is guaranteed. This is algorithmic model output, not personal investment advice.
Is GHRS stock a buy?
The TradeMates model verdict for GHRS is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.